Trail-mediated apoptosis in breast cancer cells

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chandrasekaran, Siddarth ^a   Marshall, Jocelyn R ^a   Messing, James A ^a   Hsu, Jong Wei ^a   King, Michael R ^a  

^a Cornell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD24 ANTIGEN; CD4 ANTIGEN; CYCLOOXYGENASE 2; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HERMES ANTIGEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; CYCLOOXYGENASE 2 INHIBITOR; DEATH RECEPTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BT20 CELL LINE; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MONOLAYER CULTURE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SPHEROID CELL; TUMOR SPHEROID; BIOLOGICAL MODEL; BREAST TUMOR; CELL SEPARATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE SILENCING; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; UPREGULATION;

APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL SEPARATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PHENOTYPE; RECEPTORS, DEATH DOMAIN; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84946042163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111487     Document Type: Article

References (67)

1. Geng Y, Marshall JR, King MR (2012) Glycomechanics of the Metastatic Cascade: Tumor Cell-Endothelial Cell Interactions in the Circulation. Ann Biomed Eng 40: 790-805. doi:10.1007/s10439-011-0463-6.
2. Li J, King MR (2012) Adhesion receptors as therapeutic targets for circulating tumor cells. Front Oncol 2: 79. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3402858&tool=pmcentrez&rendertype=abstract. Accessed 5 March 2013.
3. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 15170447.
4. Shi J, Zheng D, Man K, Fan S, Xu R (2003) Trail: a potential agent for cancer therapy. Curr Mol Med 3: 727-736. doi:10.2174/1566524033479401.
5. Kruyt FAE (2008) TRAIL and cancer therapy. Cancer Lett 263: 14-25.doi:10.1016/j.canlet.2008.02.003.
6. Hall MA, Cleveland JL (2007) Clearing the TRAIL for Cancer Therapy. Cancer Cell 12: 4-6. doi:10.1016/j.ccr.2007.06.011.
7. Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475. doi:10.1016/j.biocel.2007.02.007.
8. Szliszka E, Mazur B, Zydowicz G, Czuba ZP, Kró l W (2009) TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem Cytobiol 47: 579-585. doi:10.2478/ v10042-009-0111-2.
9. Zhang Y, Zhang B (2008) TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6: 1861-1871. doi:10.1158/1541-7786.MCR-08-0313.
10. Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237. doi:10.1038/sj.cgt.7700792.
11. Xu J, Zhou JY, Wei WZ, Wu GS (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5. doi:10.1371/ journal.pone.0010226.
12. LeBlanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75. doi:10.1038/sj.cdd.4401187.
13. Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14: 1091-110 8 . doi : 1 0 .1517/ 14728222.2010.519701.
14. Van Geelen CMM, Pennarun B, Boerma-Van W, Le PTK, Spierings DCJ, et al. (2010) Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol 37: 1031-1041. doi:10.3892/ijo-00000755.
15. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi:10.1016/j.yane.2012.02.046.
16. Chandrasekaran S, King MR (2012) Gather Round: In vitro tumor spheroids as improved models of in vivo tumors. J Bioeng Biomed Sci 2. doi:10.4172/2155- 9538.1000e109.
17. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, et al. (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148: 3-15. doi:10.1016/j.jbiotec.2010.01.012.
18. Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, et al. (2010) Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen 15: 820-829. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 20639504\nhttp://jbx.sagepub.com/content/15/7/820.
19. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, et al. (2013) Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene: 1-13. Available: http://www.ncbi.nlm.nih.gov/pubmed/23524583.
20. Chandrasekaran S, Giang U-BT, King MR, DeLouise LA (2011) Microenvironment induced spheroid to sheeting transition of immortalized human keratinocytes (HaCaT) cultured in microbubbles formed in polydimethylsiloxane. Biomaterials 32: 7159-7168. Available: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3148275&tool=pmcentrez&rendertype=abstract.
21. Chandrasekaran S, DeLouise LA (2011) Enriching and characterizing cancer stem cell sub-populations in the WM115 melanoma cell line. Biomaterials 32: 9316-9327. Available: http://www.ncbi.nlm.nih.gov/pubmed/21917310.
22. Chandrasekaran S, Geng Y, Delouise LA, King MR (2012) Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines. Biomaterials: 1-12. Available: http://www.ncbi.nlm. nih.gov/pubmed/22992472.
23. Geng Y, Chandrasekaran S, Hsu JW, Gidwani M, Hughes AD, et al. (2013) Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS One 8: e54959. Available: http:// www.ncbi.nlm.nih.gov/pubmed/23372803.
24. Subarsky P, Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20: 237-250. doi:10.1023/ A:1022939318102.
25. Philip B, Ito K, Moreno-Sa?nchez R, Ralph SJ (2013) HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 34: 1699-1707. Available: http://www.ncbi.nlm.nih.gov/pubmed/23740838.
26. Kaidi A, Qualtrough D, Williams AC, Paraskeva C (2006) Direct Transcriptional Up-regulation of Cyclooxygenase-2 by Hypoxia-Inducible Factor (HIF)-1 Promotes Colorectal Tumor Cell Survival and Enhances HIF-1 Transcriptional Activity during Hypoxia. Cancer Res 66: 6683-6691. Available: http:// cancerres.aacrjournals.org/content/66/13/6683.abstract.
27. Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386. doi:10.1093/carcin/bgp014.
28. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, et al. (2006) Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66: 7059-7066. doi:10.1158/0008-5472.CAN-06-0325.
29. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F (2002) Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903-4908. Available: http://www. ncbi.nlm.nih.gov/pubmed/12208739.
30. Bockhorn M, Jain RK, Munn LL (2007) Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8: 444-448. doi:10.1016/S1470-2045(07)70140-7.
31. Mitchell MJ, King MR (2013) Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors. New J Phys 15:015008. Avai l a b le: http://stacks.iop.org/1367-2630/15/i=1/ a=015008?key=crossref.8340c36723c104c4df17b0022d8199fc.
32. Rana K, Liesveld JL, King MR (2009) Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and Eselectin. Biotechnol Bioeng 102: 1692-1702. doi:10.1002/bit.22204.
33. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini P-L (2011) 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60: 319-326. doi:10.1007/s00262-010-0968-0.
34. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, et al. (2007) NK cells and cancer. J Immunol 178: 4011-4016. Available: http://www.ncbi.nlm.nih.gov/ pubmed/17371953.
35. Shi J, Zheng D, Man K, Fan S, Xu R (2003) TRAIL: a potential agent for cancer therapy. Curr Mol Med 3: 727-736. doi:10.2174/1566524033479401.
36. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783.
37. Nagane M, Huang HJ, Cavenee WK (2001) The potential of TRAIL for cancer chemotherapy. Apoptosis 6: 191-197. Available: http://www.ncbi.nlm.nih.gov/ pubmed/11388668.
38. Lane D, Cartier A, Rancourt C, Piché A (2008) Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway. Int J Gynecol Cancer 18: 670-676. doi:10.1111/j.1525-1438.2007.01062.x.
39. Koč í L, Hýžd'alová M, Vaculová A, Hofmanová J, Kozubík A (2011) Detachment-mediated resistance to TRAIL-induced apoptosis is associated with stimulation of the PI3K/Akt pathway in fetal and adenocarcinoma epithelial colon cells. Cytokine 55: 34-39. doi:10.1016/j.cyto.2011.03.013.
40. Vörsmann H, Groeber F, Walles H, Busch S, Beissert S, et al. (2013) Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis 4: e719. Available: h t t p : / / w w w . p u b m e d c e n t r a l . n i h . g o v / a r t i c l e r e n d e r . fcgi?artid=3730422&tool=pmcentrez&rendertype=abstract.
41. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, et al. (2005) Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5: 54. doi:10.1186/1471-2407-5-54.
42. Cui DD, Huang Y, Mao SH, Chen SC, Qiu M, et al. (2009) Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. Braz J Med Biol Res 42: 854-862. doi:10.1590/S0100- 879X2009000900013.
43. Muñoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodóvar C, Palacios C, López-Rivas A (2003) Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 278: 12759-12768. doi:10.1074/jbc.M212392200.
44. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, et al. (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113: 217-230. doi:10.1007/s10549-008- 9924-5.
45. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. doi:10.1038/35102167.
46. Paredes J, Cameselle-Teijeiro JF, Ricardo S, Vieira AF, Schmitt F, et al. (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64: 937-946. doi:10.1136/jcp.2011.090456.
47. Gerhard R, Paredes J, Caetano P, Gomes M, Alvarenga CA, et al. (2012) Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol. doi:10.1136/jclinpath-2012-201169.
48. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9. doi:10.1007/s10911-009-9109-9.
49. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284. doi:10.1038/nrc1590.
50. Vinogradov S, Wei X (2012) Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine 7: 597-615. doi:10.2217/nnm.12.22.
51. Li Z, Rich JN (2010) Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 345: 21-30. doi:10.1007/ 82-2010-75.
52. Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin D, et al. (2007) Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14: 1029-1038. doi:10.1677/ERC-07-0114.
53. Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, et al. (2006) COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18: 41-47.
54. Klebba I, Gupta PB, Naber SP, Arendt LM, Hinds JW, et al. (2011) Functional Heterogeneity of Breast Fibroblasts Is Defined by a Prostaglandin Secretory Phenotype that Promotes Expansion of Cancer-Stem Like Cells. PLoS One 6: e24605. doi:10.1371/journal.pone.0024605.
55. Joki T, Heese O, Nikas DC, Bello L, Zhang J, et al. (2000) Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60: 4926-4931.
56. Totzke G. , Schulze-Osthoff K., Jaä nicke RU (2003) Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22: 8021-8030. doi:10.1038/ sj.onc.1206837.
57. Nakamoto N, Higuchi H, Kanamori H, Kurita S, Tada S, et al. (2006) Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo. Int J Oncol 29: 625-635. A v a i l a b l e : h t t p : / / w w w . n c b i . n l m . n i h . g o v / e n t r e z / q u e r y . fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=16865278.
58. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, et al. (2014) An integrin b3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 16: 457-468. Available: http://www.ncbi.nlm. nih.gov/pubmed/24747441.
59. Bhardwaj N (2007) Harnessing the immune system to treat cancer. J Clin Invest 117: 1130-1136. doi:10.1172/JCI32136.
60. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117. doi:10.1146/annurev.immunol.021908.132544.
61. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281. Available: http://www.ncbi.nlm.nih.gov/pubmed/22437939.
62. Levy EM, Roberti MP, Mordoh J (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011: 676198. Available: http://www.ncbi.nlm.nih.gov/pubmed/21541191.
63. Melief CJM (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383. doi:10.1016/j.immuni.2008.08.004.
64. Van Dijk M, Halpin-McCormick a, Sessler T, Samali a, Szegezdi E (2013) Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis 4: e702. Available: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3730397&tool=pmcentrez&rendertype=abstract.
65. Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR (2014) TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A 2013: 1-6. Available: http://www.ncbi.nlm.nih.gov/pubmed/24395803.
66. Chandrasekaran S, McGuire MJ, King MR (2014) Sweeping lymph node micrometastases off their feet: an engineered model to evaluate natural killer cell mediated therapeutic intervention of circulating tumor cells that disseminate to the lymph nodes. Lab Chip. Available: http://dx.doi.org/10.1039/ C3LC50584G.
67. Xue X, Shah YM (2013) Hypoxia-inducible factor-2a is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer. Carcinogenesis 34: 163-169. Available: http://www.ncbi.nlm.nih.gov/pubmed/23042097.